Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Colombel, Jean-Frédéric"" wg kryterium: Autor


Tytuł :
The intestinal barrier, an arbitrator turned provocateur in IBD.
Autorzy :
Mehandru S; Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Precision Institute of Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Colombel JF; Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. jean-frederic.colombel@mssm.edu.
Pokaż więcej
Źródło :
Nature reviews. Gastroenterology & hepatology [Nat Rev Gastroenterol Hepatol] 2021 Feb; Vol. 18 (2), pp. 83-84.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Gastrointestinal Microbiome*
Permeability*
Colon/*metabolism
Crohn Disease/*metabolism
Intestinal Mucosa/*metabolism
Intestine, Small/*metabolism
Animals ; Antibodies, Bacterial/immunology ; Antibodies, Fungal/immunology ; Colon/immunology ; Crohn Disease/immunology ; Diet ; Enterocytes/metabolism ; Histocompatibility Antigens Class II/immunology ; Humans ; Inflammatory Bowel Diseases/immunology ; Inflammatory Bowel Diseases/metabolism ; Interleukin-10/immunology ; Intestinal Absorption ; Intestinal Mucosa/immunology ; Intestine, Small/immunology ; Intraepithelial Lymphocytes/immunology ; Macrophages ; Mice ; Mycotoxins/metabolism ; Prodromal Symptoms
Czasopismo naukowe
Tytuł :
Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases.
Autorzy :
Brenner EJ; Department of Pediatric Gastroenterology, University of North Carolina, Chapel Hill, North Carolina. Electronic address: .
Pigneur B; Hôpital Necker Enfants Malades, APHP, Université de Paris, Paris, France.
Focht G; Juliet Keidan Institute of Pediatric Gastroenterology, Shaare Zedek Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Zhang X; Department of Gastroenterology, University of North Carolina, Chapel Hill, North Carolina.
Ungaro RC; Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
Colombel JF; Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
Turner D; Juliet Keidan Institute of Pediatric Gastroenterology, Shaare Zedek Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
Kappelman MD; Department of Pediatric Gastroenterology, University of North Carolina, Chapel Hill, North Carolina.
Ruemmele FM; Hôpital Necker Enfants Malades, APHP, Université de Paris, Paris, France.
Pokaż więcej
Źródło :
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2021 Feb; Vol. 19 (2), pp. 394-396.e5. Date of Electronic Publication: 2020 Oct 12.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
COVID-19/*physiopathology
Colitis, Ulcerative/*drug therapy
Crohn Disease/*drug therapy
Systemic Inflammatory Response Syndrome/*physiopathology
Tumor Necrosis Factor Inhibitors/*therapeutic use
Adolescent ; Ambulatory Care ; COVID-19/epidemiology ; COVID-19/therapy ; Child ; Colitis, Ulcerative/epidemiology ; Comorbidity ; Crohn Disease/epidemiology ; Female ; Hospitalization ; Humans ; Inflammatory Bowel Diseases/drug therapy ; Inflammatory Bowel Diseases/epidemiology ; Male ; Mesalamine/therapeutic use ; SARS-CoV-2 ; Sulfasalazine/therapeutic use ; Systemic Inflammatory Response Syndrome/epidemiology ; Systemic Inflammatory Response Syndrome/therapy
SCR Disease Name :
Pediatric Crohn's disease; Pediatric ulcerative colitis; pediatric multisystem inflammatory disease, COVID-19 related
Czasopismo naukowe
Tytuł :
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
Autorzy :
Bohm M; Indianapolis, IN, USA.
Xu R; La Jolla, CA, USA.
Zhang Y; La Jolla, CA, USA.
Varma S; Indianapolis, IN, USA.
Fischer M; Indianapolis, IN, USA.
Kochhar G; Cleveland, OH, USA.
Boland B; La Jolla, CA, USA.
Singh S; La Jolla, CA, USA.
Hirten R; New York, NY, USA.
Ungaro R; New York, NY, USA.
Shmidt E; Minneapolis, MN, USA.
Lasch K; Deerfield, IL, USA.
Jairaith V; London, ON, Canada.
Hudesman D; New York, NY, USA.
Chang S; New York, NY, USA.
Lukin D; New York, NY, USA.
Swaminath A; New York, NY, USA.
Sands BE; New York, NY, USA.
Colombel JF; New York, NY, USA.
Kane S; Rochester, MN, USA.
Loftus EV Jr; Rochester, MN, USA.
Shen B; Cleveland, OH, USA.
Siegel CA; Lebanon, NH, USA.
Sandborn WJ; La Jolla, CA, USA.
Dulai PS; La Jolla, CA, USA.
Pokaż więcej
Corporate Authors :
VICTORY Collaboration
Źródło :
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2020 Aug; Vol. 52 (4), pp. 669-681. Date of Electronic Publication: 2020 Jul 13.
Typ publikacji :
Comparative Study; Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Crohn Disease/*drug therapy
Tumor Necrosis Factor Inhibitors/*therapeutic use
Adalimumab/therapeutic use ; Adult ; Antibodies, Monoclonal, Humanized/adverse effects ; Certolizumab Pegol/therapeutic use ; Cohort Studies ; Crohn Disease/epidemiology ; Female ; Humans ; Infliximab/therapeutic use ; Middle Aged ; Remission Induction ; Retrospective Studies ; Treatment Outcome ; Tumor Necrosis Factor Inhibitors/adverse effects ; Young Adult
Czasopismo naukowe
Tytuł :
Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial.
Autorzy :
Narula N; Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton Ontario, Canada.
Wong ECL; Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton Ontario, Canada.
Aruljothy A; Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton Ontario, Canada.
Dulai PS; Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
Colombel JF; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Marshall JK; Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton Ontario, Canada.
Ferrante M; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
Reinisch W; Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Pokaż więcej
Źródło :
The American journal of gastroenterology [Am J Gastroenterol] 2020 Aug; Vol. 115 (8), pp. 1236-1245.
Typ publikacji :
Journal Article
MeSH Terms :
Crohn Disease*
Severity of Illness Index*
Ileum/*pathology
Rectum/*pathology
Adult ; Colonoscopy ; Female ; Humans ; Male ; Prognosis
Czasopismo naukowe
Tytuł :
Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.
Autorzy :
Ungaro RC; Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, New York.
Yzet C; Amiens University Hospital, Department of Gastroenterology, Amiens, France.
Bossuyt P; Imelda Gastroenterology Clinical Research Center, Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium.
Baert FJ; AZ Delta Roeselare, Roeselare, Belgium.
Vanasek T; Second Department of Internal Medicine, University Hospital Hradec Králové, Hradec Králové, Czech Republic.
D'Haens GR; Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Joustra VW; Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Panaccione R; Inflammatory Bowel Disease Unit, University of Calgary, Calgary, Canada.
Novacek G; Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Reinisch W; Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
Armuzzi A; Inflammatory Bowel Disease Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS-Università Cattolica del Sacro Cuore, Rome, Italy.
Golovchenko O; Medical Clinical Investigational Center of Medical Center Health Clinic LLC, Vinnytsia, Ukraine.
Prymak O; Medical Clinical Investigational Center of Medical Center Health Clinic LLC, Vinnytsia, Ukraine.
Goldis A; Universitatea de Medicina si Farmacie, Timisoara, Romania.
Travis SP; Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, United Kingdom.
Hébuterne X; Gastroenterology and Clinical Nutrition Department, Centre Hospitalier Universitaire of Nice, University of Nice Sophia-Antipolis, Nice, France.
Ferrante M; University Hospitals Leuven, Leuven, Belgium.
Rogler G; Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
Fumery M; Amiens University Hospital, Department of Gastroenterology, Amiens, France.
Danese S; Humanitas University, Istituto Clinico Humanitas, Milan, Italy.
Rydzewska G; Central Clinical Hospital of Ministry of Interior and Administration in Warsaw, Warsaw, Poland.
Pariente B; Claude Huriez Hospital, Lille University, Lille, France.
Hertervig E; Skane University Hospital, Lund, Sweden.
Stanciu C; Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
Serrero M; Hepato-Gastroenterology Department, North Hospital, University of Mediterranean, Marseille, France.
Diculescu M; University of Medicine and Pharmacy 'Carol Davila,' Bucharest, Romania.
Peyrin-Biroulet L; Hépato Gastro-Entérologie, Hôpital de Brabois, Nancy, France.
Laharie D; Service d'Hépato-gastroentérologie et Oncologie Digestive, Hôpital Haut-Lévêque, Bordeaux, France.
Wright JP; Kingsbury Hospital, Cape Town, South Africa.
Gomollón F; Hospital Clínico de Zaragoza, IIS Aragón, Zaragoza, Spain.
Gubonina I; Military Medical Academy named after S.M. Kirov, Saint Petersburg, Russian Federation.
Schreiber S; Department of Internal Medicine I, Kiel University, Kiel, Germany.
Motoya S; Inflammatory Bowel Disease Center, Sapporo Kosei General Hospital, Sapporo, Japan.
Hellström PM; Uppsala University Hospital, Uppsala, Sweden.
Halfvarson J; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Butler JW; AbbVie, Inc, North Chicago, Illinois.
Petersson J; AbbVie, Inc, North Chicago, Illinois.
Petralia F; Department of Genetics and Genomic Sciences and Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, New York.
Colombel JF; Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, New York. Electronic address: jean-frederic.colombel@mssm.edu.
Pokaż więcej
Źródło :
Gastroenterology [Gastroenterology] 2020 Jul; Vol. 159 (1), pp. 139-147. Date of Electronic Publication: 2020 Mar 26.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-Inflammatory Agents/*administration & dosage
Crohn Disease/*drug therapy
Adalimumab/administration & dosage ; Adalimumab/adverse effects ; Adult ; Anti-Inflammatory Agents/adverse effects ; Azathioprine/administration & dosage ; Azathioprine/adverse effects ; Crohn Disease/diagnosis ; Crohn Disease/immunology ; Crohn Disease/pathology ; Disease Progression ; Drug Therapy, Combination/adverse effects ; Drug Therapy, Combination/methods ; Female ; Follow-Up Studies ; Hospitalization/statistics & numerical data ; Humans ; Male ; Prednisone/administration & dosage ; Prednisone/adverse effects ; Remission Induction/methods ; Retrospective Studies ; Severity of Illness Index ; Time Factors ; Treatment Outcome ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Tumor Necrosis Factor-alpha/immunology ; Young Adult
Czasopismo naukowe
Tytuł :
Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis.
Autorzy :
Torres J; Department of Medicine, Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York; Gastroenterology Division, Hospital Beatriz Ângelo, Loures, Lisbon, Portugal.
Petralia F; Department of Genetics and Genomic Sciences, Icahn School of Medicine, New York City, New York.
Sato T; Janssen Research and Development, Spring House (Ambler), Pennsylvania.
Wang P; Department of Genetics and Genomic Sciences, Icahn School of Medicine, New York City, New York.
Telesco SE; Janssen Research and Development, Spring House (Ambler), Pennsylvania.
Choung RS; Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Strauss R; Janssen Research and Development, Spring House (Ambler), Pennsylvania.
Li XJ; Prometheus Laboratories, San Diego, California.
Laird RM; Enteric Diseases Department, Naval Medical Research Center, Silver Spring, Maryland.
Gutierrez RL; Enteric Diseases Department, Naval Medical Research Center, Silver Spring, Maryland.
Porter CK; Enteric Diseases Department, Naval Medical Research Center, Silver Spring, Maryland.
Plevy S; Janssen Research and Development, Spring House (Ambler), Pennsylvania.
Princen F; Prometheus Laboratories, San Diego, California.
Murray JA; Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Riddle MS; Enteric Diseases Department, Naval Medical Research Center, Silver Spring, Maryland; Department of Preventive Medicine and Biostatistics, Uniformed Services University, Bethesda, Maryland. Electronic address: .
Colombel JF; Department of Medicine, Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: jean-frederic.colombel@mssm.edu.
Pokaż więcej
Źródło :
Gastroenterology [Gastroenterology] 2020 Jul; Vol. 159 (1), pp. 96-104. Date of Electronic Publication: 2020 Mar 09.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Antineutrophil Cytoplasmic/*blood
Antibodies, Bacterial/*blood
Antibodies, Fungal/*blood
Colitis, Ulcerative/*diagnosis
Crohn Disease/*diagnosis
Adult ; Antibodies, Antineutrophil Cytoplasmic/immunology ; Antibodies, Bacterial/immunology ; Antibodies, Fungal/immunology ; Biomarkers/blood ; Case-Control Studies ; Colitis, Ulcerative/blood ; Colitis, Ulcerative/immunology ; Crohn Disease/blood ; Crohn Disease/immunology ; Escherichia coli/immunology ; Female ; Healthy Volunteers ; Humans ; Immunity, Innate ; Male ; Models, Statistical ; Predictive Value of Tests ; Prognosis ; Proteomics ; ROC Curve ; Saccharomyces cerevisiae/immunology ; Time Factors ; Young Adult
Czasopismo naukowe
Tytuł :
Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease.
Autorzy :
Chapman TP; Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, UK.
Frias Gomes C; Surgical Department, Gastroenterology Division, Hospital Beatriz Ângelo, Loures, Portugal.
Louis E; Department of Gastroenterology, CHU Liège University Hospital, Liège, Belgium.
Colombel JF; The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
Satsangi J; Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, UK.
Pokaż więcej
Źródło :
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2020 Jul; Vol. 52 (1), pp. 73-84. Date of Electronic Publication: 2020 May 26.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Aminosalicylic Acids/*therapeutic use
Colitis, Ulcerative/*drug therapy
Crohn Disease/*drug therapy
Colorectal Neoplasms/prevention & control ; Humans ; Randomized Controlled Trials as Topic ; Withholding Treatment
Czasopismo naukowe
Tytuł :
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
Autorzy :
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, California.
Feagan BG; Western University, Robarts Clinical Trials, St Joseph's Health Care, London, Ontario, Canada.
Loftus EV Jr; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Peyrin-Biroulet L; Department of Gastroenterology and Inserm U1256 Nutrition-Génétique et Exposition aux Risques Environnementaux, niversity of Lorraine, Nancy, France.
Van Assche G; Department of Gastroenterology and Hepatology, University of Leuven, Leuven, Belgium.
D'Haens G; Department of Gastroenterology, Amsterdam University Medical Center campus Academic Medical Center, Amsterdam, The Netherlands.
Schreiber S; Department of Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.
Colombel JF; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
Lewis JD; Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Ghosh S; University of Birmingham, National Institute for Health Research Biomedical Research Centre, Birmingham, United Kingdom.
Armuzzi A; Presidio Columbus, Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico Università Cattolica del Sacro Cuore, Rome, Italy.
Scherl E; Weill Department of Medicine, New York Presbyterian Hospital Weill Cornell Medicine, New York, New York.
Herfarth H; Department of Medicine, University of North Carolina, Chapel Hill, North Carolina.
Vitale L; AbbVie Inc., North Chicago, Illinois.
Mohamed MF; AbbVie Inc., North Chicago, Illinois.
Othman AA; AbbVie Inc., North Chicago, Illinois.
Zhou Q; AbbVie Inc., North Chicago, Illinois.
Huang B; AbbVie Inc., North Chicago, Illinois.
Thakkar RB; AbbVie Inc., North Chicago, Illinois.
Pangan AL; AbbVie Inc., North Chicago, Illinois.
Lacerda AP; AbbVie Inc., North Chicago, Illinois.
Panes J; Inflammatory Bowel Diseases Unit, Hospital Clínic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain. Electronic address: .
Pokaż więcej
Źródło :
Gastroenterology [Gastroenterology] 2020 Jun; Vol. 158 (8), pp. 2123-2138.e8. Date of Electronic Publication: 2020 Feb 08.
Typ publikacji :
Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Crohn Disease/*drug therapy
Gastrointestinal Agents/*administration & dosage
Heterocyclic Compounds, 3-Ring/*administration & dosage
Janus Kinase Inhibitors/*administration & dosage
Adult ; Aged ; Colonoscopy ; Crohn Disease/diagnosis ; Crohn Disease/immunology ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Gastrointestinal Agents/adverse effects ; Gastrointestinal Agents/pharmacokinetics ; Heterocyclic Compounds, 3-Ring/adverse effects ; Heterocyclic Compounds, 3-Ring/pharmacokinetics ; Humans ; Janus Kinase Inhibitors/adverse effects ; Janus Kinase Inhibitors/pharmacokinetics ; Male ; Middle Aged ; Remission Induction ; Severity of Illness Index ; Time Factors ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease.
Autorzy :
Ungaro RC; The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Aggarwal S; NOVEL Health Strategies, Bethesda, MD, USA.
Topaloglu O; NOVEL Health Strategies, Bethesda, MD, USA.
Lee WJ; Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA.
Clark R; Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL, USA.
Colombel JF; The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Pokaż więcej
Źródło :
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2020 May; Vol. 51 (9), pp. 831-842. Date of Electronic Publication: 2020 Mar 23.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :
Biological Products/*therapeutic use
Crohn Disease/*drug therapy
Adult ; Age Factors ; Child ; Crohn Disease/epidemiology ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Humans ; Prospective Studies ; Recurrence ; Remission Induction ; Treatment Outcome
SCR Disease Name :
Pediatric Crohn's disease
Czasopismo naukowe
Tytuł :
Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.
Autorzy :
Panaccione R; Inflammatory Bowel Disease Unit, University of Calgary, Calgary, Alberta, Canada.
Colombel JF; Division of Gastroenterology, Icahn School of Medicine Vanasek, Division of Gastroenterology and Hepatology, New York, New York, USA.
Travis SPL; Gastroenterology, John Radcliffe Hospital, Oxford, UK.
Bossuyt P; Gastroenterology, Imelda General Hospital, Bonheiden, Belgium.
Baert F; Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium.
Vaňásek T; Division of Gastroenterology and Hepatology, Hepato-Gastroenterologie HK, sro, Hradec Králové, Czech Republic.
Danalıoğlu A; Gastroenterology Department, Bezmialem Vakıf University, Istanbul, Turkey.
Novacek G; Department of Internal Medicine IV, Medical University of Vienna, Vienna, Austria.
Armuzzi A; Internal Medicine and Gastroenterology, Catholic University, Rome, Italy.
Reinisch W; Department of Medicine IV, Medical University Vienna, Vienna, Austria.
Johnson S; Medicus Economics LCC., Milton, Maine, USA.
Buessing M; Medicus Economics, Boston, Massachusetts, USA.
Neimark E; AbbVie Inc., North Chicago, Illinois, USA.
Petersson J; AbbVie Inc., North Chicago, Illinois, USA.
Lee WJ; AbbVie Inc., North Chicago, Illinois, USA.
D'Haens GR; Gastroenterology, AMC, Amsterdam, The Netherlands.
Pokaż więcej
Źródło :
Gut [Gut] 2020 Apr; Vol. 69 (4), pp. 658-664. Date of Electronic Publication: 2019 Jul 08.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Adalimumab/*therapeutic use
Anti-Inflammatory Agents/*therapeutic use
Crohn Disease/*drug therapy
Biomarkers/metabolism ; C-Reactive Protein/metabolism ; Cost-Benefit Analysis ; Crohn Disease/metabolism ; Hospitalization ; Humans ; Leukocyte L1 Antigen Complex/metabolism ; Quality-Adjusted Life Years ; Symptom Assessment ; Treatment Outcome ; United Kingdom
Czasopismo naukowe
Tytuł :
A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease.
Autorzy :
Dulai PS; La Jolla, CA, USA.
Amiot A; Creteil, France.
Peyrin-Biroulet L; Nancy, France.
Jairath V; London, ON, Canada.
Serrero M; Marseille, France.
Filippi J; Nice, France.
Singh S; La Jolla, CA, USA.
Pariente B; Lille, France.
Loftus EV Jr; Rochester, MN, USA.
Roblin X; Saint-Etienne, France.
Kane S; Rochester, MN, USA.
Buisson A; Clermont-Ferrand, France.
Siegel CA; Lebanon, NH, USA.
Bouhnik Y; Clichy, France.
Sandborn WJ; La Jolla, CA, USA.
Lasch K; Deerfield, IL, USA.
Rosario M; Deerfield, IL, USA.
Feagan BG; London, ON, Canada.
Bojic D; Zurich, Switzerland.
Trang-Poisson C; Nantes, France.
Shen B; Cleveland, OH, USA.
Altwegg R; Montpellier, France.
Sands BE; New York, NY, USA.
Colombel JF; New York, NY, USA.
Carbonnel F; Paris, France.
Pokaż więcej
Corporate Authors :
GETAID OBSERV-IBD, VICTORY Cohorts Collaboration*
Źródło :
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2020 Mar; Vol. 51 (5), pp. 553-564. Date of Electronic Publication: 2019 Dec 22.
Typ publikacji :
Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Decision Support Systems, Clinical*
Patient Selection*
Antibodies, Monoclonal, Humanized/*therapeutic use
Crohn Disease/*drug therapy
Drug Monitoring/*standards
Gastrointestinal Agents/*therapeutic use
Adult ; Algorithms ; Calibration ; Cohort Studies ; Crohn Disease/epidemiology ; Drug Monitoring/methods ; Female ; Humans ; Male ; Middle Aged ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
New Blood Marker of Endoscopic Disease Activity-A Step Forward in Treating Crohn's Disease to Target?
Autorzy :
Agrawal M; The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
Ungaro RC; The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
Colombel JF; The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: jean-frederic.colombel@mssm.edu.
Pokaż więcej
Źródło :
Gastroenterology [Gastroenterology] 2020 Feb; Vol. 158 (3), pp. 463-465. Date of Electronic Publication: 2019 Dec 19.
Typ publikacji :
Editorial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Comment
MeSH Terms :
Crohn Disease*
Biomarkers ; Endoscopy, Gastrointestinal ; Humans
Raport
Tytuł :
Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease.
Autorzy :
Lewis JD; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Rutgeerts P; Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium.
Feagan BG; Department of Medicine, University of Western Ontario, London, Ontario, Canada.
D'haens G; Academic Medical Center, Amsterdam, the Netherlands.
Danese S; Department of Gastroenterology, Istituto Clinico Humanitas, Rozzano, Milan, Italy.
Colombel JF; Icahn School of Medicine at Mt Sinai, New York, New York, USA.
Reinisch W; Division of Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria.
Rubin DT; University of Chicago Inflammatory Bowel Disease Center, Chicago, Illinois, USA.
Selinger C; Leeds Gastroenterology Institute, St James University Hospital, Leeds, United Kingdom.
Bewtra M; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Barcomb L; AbbVie Inc., North Chicago, Illinois, USA.
Lacerda AP; AbbVie Inc., North Chicago, Illinois, USA.
Wallace K; AbbVie Inc., North Chicago, Illinois, USA.
Butler JW; AbbVie Inc., North Chicago, Illinois, USA.
Wu M; AbbVie Inc., North Chicago, Illinois, USA.
Zhou Q; AbbVie Inc., North Chicago, Illinois, USA.
Liao X; AbbVie Inc., North Chicago, Illinois, USA.
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
Pokaż więcej
Źródło :
Inflammatory bowel diseases [Inflamm Bowel Dis] 2020 Jan 06; Vol. 26 (2), pp. 304-313.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Severity of Illness Index*
Abdominal Pain/*diagnosis
Anti-Inflammatory Agents/*therapeutic use
Constipation/*diagnosis
Crohn Disease/*drug therapy
Diarrhea/*diagnosis
Endoscopy, Gastrointestinal/*methods
Abdominal Pain/chemically induced ; Adult ; Clinical Trials as Topic ; Constipation/chemically induced ; Crohn Disease/pathology ; Diarrhea/chemically induced ; Drug Monitoring ; Endpoint Determination/standards ; Female ; Follow-Up Studies ; Humans ; Intestinal Mucosa/drug effects ; Male ; Prognosis ; Research Design ; Wound Healing/drug effects
Czasopismo naukowe
Tytuł :
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
Autorzy :
Hanauer SB; Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Sandborn WJ; University of California San Diego, La Jolla, CA USA.
Feagan BG; Robarts Clinical Trials, Western University, London, ON, Canada.
Gasink C; Janssen Scientific Affairs, LLC, Horsham, PA, USA.
Jacobstein D; Janssen Research & Development, LLC, Spring House, PA, USA.
Zou B; Janssen Research & Development, LLC, Spring House, PA, USA.
Johanns J; Janssen Research & Development, LLC, Spring House, PA, USA.
Adedokun OJ; Janssen Research & Development, LLC, Spring House, PA, USA.
Sands BE; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Rutgeerts P; University Hospital, Gasthuisberg, Leuven, Belgium.
de Villiers WJS; Stellenbosch University, Stellenbosch, South Africa.
Colombel JF; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ghosh S; NIHR Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK.
Pokaż więcej
Źródło :
Journal of Crohn's & colitis [J Crohns Colitis] 2020 Jan 01; Vol. 14 (1), pp. 23-32.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Crohn Disease/*drug therapy
Ustekinumab/*therapeutic use
Double-Blind Method ; Drug Administration Schedule ; Humans ; Injections, Subcutaneous ; Maintenance Chemotherapy ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
Autorzy :
Faleck DM; Icahn School of Medicine at Mount Sinai, New York, New York.
Winters A; Icahn School of Medicine at Mount Sinai, New York, New York.
Chablaney S; Icahn School of Medicine at Mount Sinai, New York, New York.
Shashi P; Cleveland Clinic Foundation, Cleveland, Ohio.
Meserve J; University of California - San Diego, La Jolla, California.
Weiss A; Montefiore Medical Center, Bronx, New York.
Aniwan S; Mayo Clinic, Rochester, Minnesota.
Koliani-Pace JL; Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Kochhar G; Cleveland Clinic Foundation, Cleveland, Ohio.
Boland BS; University of California - San Diego, La Jolla, California.
Singh S; University of California - San Diego, La Jolla, California.
Hirten R; Icahn School of Medicine at Mount Sinai, New York, New York.
Shmidt E; University of Minnesota, Minneapolis, Minnesota.
Kesar V; Lenox Hill Hospital, New York, New York.
Lasch K; Takeda Pharmaceuticals U.S.A., Inc, Deerfield, Illinois.
Luo M; Takeda Pharmaceuticals U.S.A., Inc, Deerfield, Illinois.
Bohm M; Indiana University, Indianapolis, Indiana.
Varma S; Indiana University, Indianapolis, Indiana.
Fischer M; Indiana University, Indianapolis, Indiana.
Hudesman D; New York University, New York, New York.
Chang S; New York University, New York, New York.
Lukin D; Montefiore Medical Center, Bronx, New York.
Sultan K; North Shore University Hospital, Manhasset, New York.
Swaminath A; Lenox Hill Hospital, New York, New York.
Gupta N; University of Mississippi, Jackson, Mississippi.
Siegel CA; Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Shen B; Cleveland Clinic Foundation, Cleveland, Ohio.
Sandborn WJ; University of California - San Diego, La Jolla, California.
Kane S; Mayo Clinic, Rochester, Minnesota.
Loftus EV Jr; Mayo Clinic, Rochester, Minnesota.
Sands BE; Icahn School of Medicine at Mount Sinai, New York, New York.
Colombel JF; Icahn School of Medicine at Mount Sinai, New York, New York.
Dulai PS; University of California - San Diego, La Jolla, California. Electronic address: .
Ungaro R; Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: .
Pokaż więcej
Źródło :
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2019 Nov; Vol. 17 (12), pp. 2497-2505.e1. Date of Electronic Publication: 2019 Jan 06.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Remission Induction*
Antibodies, Monoclonal, Humanized/*therapeutic use
Colitis, Ulcerative/*drug therapy
Crohn Disease/*drug therapy
Gastrointestinal Agents/*therapeutic use
Adult ; Endoscopy, Digestive System ; Female ; Humans ; Male ; Middle Aged ; Registries ; Retrospective Studies ; Time Factors ; Young Adult
Czasopismo naukowe
Tytuł :
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes.
Autorzy :
Koliani-Pace JL; Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Singh S; University of California, San Diego, La Jolla, California, USA.
Luo M; Takeda Pharmaceuticals U.S.A., Inc., Deerfield, Illinois, USA.
Hirten R; Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Aniwan S; Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.; Mayo Clinic, Rochester, Minnesota, USA.
Kochhar G; Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Chang S; New York University, New York, New York, USA.
Lukin D; Montefiore Medical Center, New York, New York, USA.
Gao Y; North Shore University Hospital, Manhasset, New York, USA.
Bohm M; Indiana University, Indianapolis, Indiana, USA.
Swaminath A; Lenox Hill Hospital, New York, New York, USA.
Gupta N; University of Minnesota, Minneapolis, Minnesota, USA.
Shmidt E; University of Mississippi, Jackson, Mississippi, USA.
Meserve J; University of California, San Diego, La Jolla, California, USA.
Winters A; Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Chablaney S; Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Faleck DM; Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Yang J; Takeda Pharmaceuticals U.S.A., Inc., Deerfield, Illinois, USA.
Huang Z; Takeda Pharmaceuticals U.S.A., Inc., Deerfield, Illinois, USA.
Boland BS; University of California, San Diego, La Jolla, California, USA.
Shashi P; Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Weiss A; New York University, New York, New York, USA.
Hudesman D; University of California, San Diego, La Jolla, California, USA.
Varma S; Indiana University, Indianapolis, Indiana, USA.
Fischer M; Indiana University, Indianapolis, Indiana, USA.
Sultan K; North Shore University Hospital, Manhasset, New York, USA.
Shen B; Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Kane S; Mayo Clinic, Rochester, Minnesota, USA.
Loftus EV; Mayo Clinic, Rochester, Minnesota, USA.
Sands BE; Mayo Clinic, Rochester, Minnesota, USA.
Colombel JF; Mayo Clinic, Rochester, Minnesota, USA.
Sandborn WJ; University of California, San Diego, La Jolla, California, USA.
Lasch K; Takeda Pharmaceuticals U.S.A., Inc., Deerfield, Illinois, USA.
Siegel CA; Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Dulai PS; University of California, San Diego, La Jolla, California, USA.
Pokaż więcej
Źródło :
Inflammatory bowel diseases [Inflamm Bowel Dis] 2019 Oct 18; Vol. 25 (11), pp. 1854-1861.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Colitis, Ulcerative/*drug therapy
Crohn Disease/*drug therapy
Gastrointestinal Agents/*therapeutic use
Hospitalization/*statistics & numerical data
Surgical Procedures, Operative/*statistics & numerical data
Adult ; Colitis, Ulcerative/surgery ; Crohn Disease/surgery ; Databases, Factual ; Female ; Hospitalization/trends ; Humans ; Male ; Middle Aged ; Remission Induction ; Retrospective Studies ; Surgical Procedures, Operative/trends ; United States ; Wound Healing
Czasopismo naukowe
Tytuł :
Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.
Autorzy :
Danese S; IBD Center, Humanitas Clinical and Research Center, Humanitas University, Rozzano, Milan, Italy. Electronic address: .
Sandborn WJ; University of California, San Diego, La Jolla, California.
Colombel JF; Icahn School of Medicine at Mount Sinai, New York City, New York.
Vermeire S; University Hospitals Leuven, Leuven, Belgium.
Glover SC; University of Florida, Gainesville, Florida.
Rimola J; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
Siegelman J; Takeda Development Center Americas Inc., Cambridge, Massachusetts.
Jones S; Takeda Development Centre Europe Ltd, London, UK.
Bornstein JD; Takeda Development Center Americas Inc., Cambridge, Massachusetts.
Feagan BG; Robarts Clinical Trials, Western University, London, Ontario, Canada.
Pokaż więcej
Źródło :
Gastroenterology [Gastroenterology] 2019 Oct; Vol. 157 (4), pp. 1007-1018.e7. Date of Electronic Publication: 2019 Jul 04.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Endoscopy, Gastrointestinal*
Magnetic Resonance Imaging*
Anti-Inflammatory Agents/*therapeutic use
Antibodies, Monoclonal, Humanized/*therapeutic use
Crohn Disease/*drug therapy
Gastrointestinal Agents/*therapeutic use
Intestinal Mucosa/*drug effects
Wound Healing/*drug effects
Adult ; Anti-Inflammatory Agents/adverse effects ; Antibodies, Monoclonal, Humanized/adverse effects ; Biopsy ; Crohn Disease/diagnostic imaging ; Crohn Disease/pathology ; Female ; Gastrointestinal Agents/adverse effects ; Humans ; Intestinal Mucosa/diagnostic imaging ; Intestinal Mucosa/pathology ; Male ; Middle Aged ; Predictive Value of Tests ; Prospective Studies ; Quality of Life ; Remission Induction ; Time Factors ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Treating Inflammatory Bowel Disease With Diet: A Taste Test.
Autorzy :
Sabino J; The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Gastroenterology, University Hospitals of Leuven, Leuven, Belgium.
Lewis JD; Department of Medicine, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pennsylvania.
Colombel JF; The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: jean-frederic.colombel@mssm.edu.
Pokaż więcej
Źródło :
Gastroenterology [Gastroenterology] 2019 Aug; Vol. 157 (2), pp. 295-297. Date of Electronic Publication: 2019 Jun 27.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Crohn Disease*
Inflammatory Bowel Diseases*
Diet ; Enteral Nutrition ; Humans ; Taste
Opinia redakcyjna
Tytuł :
Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat?
Autorzy :
Agrawal M; Division of Gastroenterology, Lenox Hill Hospital, Northwell Health, 100 East 77th Street, New York, NY 10075, USA. Electronic address: .
Colombel JF; Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, 1428 Madison Avenue, New York, NY 10029, USA.
Pokaż więcej
Źródło :
Gastrointestinal endoscopy clinics of North America [Gastrointest Endosc Clin N Am] 2019 Jul; Vol. 29 (3), pp. 421-436. Date of Electronic Publication: 2019 Apr 06.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Colitis, Ulcerative/*therapy
Crohn Disease/*therapy
Inflammatory Bowel Diseases/*therapy
Remission Induction/*methods
Clinical Decision-Making ; Humans
Czasopismo naukowe
Tytuł :
Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.
Autorzy :
Colombel JF; Department of Gastroenterology, Icahn School of Medicine, Mount Sinai Medical Center, New York, New York. Electronic address: jean-frederic.colombel@mssm.edu.
Adedokun OJ; Janssen Research & Development, Spring House, Pennsylvania.
Gasink C; Janssen Scientific Affairs, Horsham, Pennsylvania.
Gao LL; Janssen Scientific Affairs, Horsham, Pennsylvania.
Cornillie FJ; MSD International, Kriens, Switzerland.
D'Haens GR; Department of Gastroenterology, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.
Rutgeerts PJ; Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium.
Reinisch W; Universitätsklinik für Innere Medizin III, Vienna, Austria.
Sandborn WJ; Division of Gastroenterology and Department of Medicine, University of California, San Diego, San Diego, California.
Hanauer SB; Department of Medicine, Digestive Health Center, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
Pokaż więcej
Źródło :
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2019 Jul; Vol. 17 (8), pp. 1525-1532.e1. Date of Electronic Publication: 2018 Sep 26.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Azathioprine/*pharmacokinetics
Crohn Disease/*drug therapy
Infliximab/*pharmacokinetics
Remission Induction/*methods
Adult ; Crohn Disease/blood ; Drug Therapy, Combination ; Female ; Gastrointestinal Agents/pharmacokinetics ; Humans ; Immunosuppressive Agents/pharmacokinetics ; Male ; Middle Aged ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies